The Line Between Food and Poison Is Blurrier Than Your Supplement Label Suggests
RapAdmin
Two toxicologists at Maastricht University argue that the public and regulatory distinction between healthy food and toxic food does not survive scrutiny, and they illustrate this with ten short examples. Their central claim is that mild toxicity is often the mechanism of benefit rather than its opposite. Flavonoids appear to work partly through reactive chemistry that activates cellular defense pathways. High-dose vitamin B6 supplementation can produce nerve damage resembling B6 deficiency because the supplemented form competes with the active form. Natural compounds dominate dietary exposure to plant-defense chemicals, undercutting the assumption that natural equals safe. The authors also note a regulatory asymmetry: health claims demand rigorous trial evidence while risk regulation proceeds on precaution alone. They propose a graded concept of health risk to mirror how toxic risk is handled.
The paper opens with food tasters in ancient Egypt and Rome, employed to die so that rulers would not. The authors call them early toxicologists, with a wink, and the point they build from it is serious: for most of human history the test for whether food was safe was whether the person who ate it survived. We have better tools now, but the underlying category, safe versus poisonous, turns out to be far less tidy than either consumers or regulators behave as though it is.
The argument runs through ten short vignettes. Several are familiar to anyone who follows the field. The belief that natural compounds are inherently safe is unfounded, and the authors lean on a well-known 1990 estimate that the overwhelming majority by weight of pesticides in the American diet are chemicals that plants manufacture themselves. Chemophobia and its mirror image, an uncritical affection for anything labeled natural, are presented as emotional responses rather than evidence-based positions.
The more interesting material concerns hormesis. This is the observation that many compounds show a biphasic dose response: harmful at high doses, beneficial at low ones. The conventional regulatory model assumes a straight line from high-dose animal data down to real-world exposure, which ignores that cells have evolved machinery to detoxify and adapt. The authors argue that low-level stress is not a watered-down version of poisoning but a qualitatively different thing, an invitation for the body to upgrade its defenses.
Flavonoids are their worked example. These compounds are marketed as antioxidants, which suggests they neutralize damage. The authors point to a different picture. Once oxidized, flavonoids become reactive toward thiol groups, which a toxicologist would ordinarily flag as a damage mechanism. That reactivity activates Nrf2, a transcription factor that switches on a broad set of protective genes. The protective effect outlasts and exceeds anything simple radical scavenging could provide. The supposed toxicity is the delivery mechanism for the benefit.
The vitamin B6 example is the cleanest in the paper. Severe deficiency causes nerve damage. So does high-dose supplementation, which looks paradoxical until you notice that supplements almost always contain pyridoxine, which the body must convert into the active form. At high concentrations, the unconverted form appears to compete with the active one at the enzymes that need it. Too much of the supplement produces a functional shortage of the vitamin.
Two more threads deserve attention. The authors note that food and drug interactions are discussed almost entirely as hazards, when some combinations are beneficial. And they argue that the 1948 definition of health as complete wellbeing has outlived its usefulness, proposing instead that health is the ability to adapt. If that reframing is right, then the goal of a health-promoting diet is not to minimize all stress but to improve the capacity to handle it, which is a different target and would need different measurements.
The closing line is the authors’ own summary: the bitter taste of toxins becomes sweeter if toxicity leads to healthiness. It is a good line. Whether it is a good basis for deciding what to put in your body is a separate question, and the paper does not answer it.
Actionable Insights
This is an opinion piece. It contains no trial, no dose-response curve, and no quantitative outcome. That said, four points have practical teeth.
- Vitamin B6 has a real and low ceiling. The paper describes the mechanism but gives no number. The number exists: European regulators concluded in 2023 that the relationship between excess vitamin B6 intake and peripheral neuropathy is well established, set a reference point of 50 mg/day from case-control data, and established a tolerable upper intake level of 12 mg/day for adults. That revision halved the prior limit of 25 mg/day set in 2000, and the US National Academy of Medicine still uses 100 mg/day, a point critics of the revision have pressed. Most people do not approach these levels from food; regular users of high-dose supplements do. If you take a B-complex, read the label. Many contain 25 to 100 mg. Practical move: prefer the active form, pyridoxal-5-phosphate, over pyridoxine if you supplement at all, since the proposed mechanism of harm is specific to the unconverted form. www.pubmed.gov
- The hormesis framing supports interventions you can actually dose, and those are mostly not pills. Exercise, heat and cold exposure, and caloric restriction are the best-characterized hormetic stressors in humans, with dose-response curves that are at least partly understood. The flavonoid version of the same logic is far less mapped. The paper itself lists five unanswered questions for applying hormesis: optimal dose, frequency, duration, timing, synergy between stimuli, kinetics of the response, modification by age and sex, and whether adverse effects occur. Until those are answered for a given compound, “a little toxicity is good for you” is a hypothesis, not a dosing protocol. Note the direction this cuts: it argues against megadosing polyphenol supplements, not for it, because the benefit sits in a window and more is not better.
- Take the asymmetry seriously in both directions. The authors are right that health claims face a higher evidentiary bar than risk claims. The practical consequence for a consumer is the opposite of what the framing suggests: an authorized health claim is relatively trustworthy precisely because the bar is high, while the absence of a claim tells you little. Treat unclaimed benefits as unproven rather than as suppressed truth.
- Flag food-drug interactions in both directions with your prescriber. The paper’s examples include flavonoids enhancing corticosteroid response and grapefruit juice assisting cortisol replacement by altering drug-metabolizing enzymes. The same enzyme modulation that helps in one case causes harm in another. A beneficial interaction is still an interaction and still needs monitoring.
Context and Source
- Open Access Paper: Exploring health and toxicity in food choices: 10 examples navigating the gray area, published 5 January 2024
- Article type: Mini Review..
- Institutions: University College Venlo, Maastricht University; Department of Pharmacology and Toxicology, Faculty of Health, Medicine and Life Sciences, Maastricht University
- Country: Netherlands
- Journal: Frontiers in Nutrition
- Impact evaluation: The impact score of this journal is 5.5, evaluated against a typical high-end range of 0-60+ for top general science, therefore this is a Medium impact journal.









